| Disease Name : | Malignant glioma |
| Regulator : | BCYRN1 |
| Target : | CUEDC2 |
| Clinical application : | |
| Regulator dysregulation in Circulating Tumor Cells : | UP(LIHC,PRAD,SKCM,BRCA);DATA(GSE117623,GSE104209,GSE38495,GSE55807) |
| Target dysregulation in Circulating Tumor Cells : | DOWN(LIHC,NSCLC,PRAD,PAAD,BRCA);UP(PAAD,BRCA);DATA(GSE117623,GSE74639,GSE40174,GSE104209,GSE60407,GSE111842,GSE55807) |
| Regulatory Type : | regulation |
| Level Of Regulation : | RNA-protein |
| Regulation Direction : | positively-E |
| Experimental method for lncRNA-target : | RNA pull-down assay;western blot;luciferase reporter assay |
| Expression Pattern : | downregulation |
| Experimental method for lncRNA expression : | qRT-PCR |
| Data Accession : | |
| Influenced Function : | cell proliferation(-);cell migration(-) |
| Regulatory Mechanism : | ceRNA(miR-619-5p) |
| Drugs : | |
| Cancer Stem Cell : | |
| Hallmark : | Insensitivity to Antigrowth Signals |
| Disease Category : | Cancer |
| Disease Name2 : | Brain glioma |
| Regulator Type : | lncRNA |
| Target Type : | PCG |
| Regulator EnsembleID : | ENSG00000236824 |
| Target EnsembleID : | ENSG00000107874 |
| Regulator EntrezID : | 618 |
| Target EntrezID: | 79004 |
| RegulatorAlias : | BC200|BC200a|LINC00004|NCRNA00004 |
| TargetAlias : | C10orf66|MGC2491 |
| Regulator Location : | GRCh38_2:47335315-47335514 |
| Target Location : | |
| Evidence : | LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway Differential RNA transcripts and BCYRN1 were identified by RT-qPCR in glioma samples and controls. CCK-8, colony formation assays, flow cytometry, TUNEL assays, cell migration assays, wound-healing assays, and xenograft model were established to investigate the biological function of BCYRN1 both in vitro and in vivo. Various bioinformatics analysis, dual-luciferase reporter assays, biotinylated RNA pull-down assays, and rescue experiments were conducted to reveal the underlying mechanisms of competitive endogenous RNAs (ceRNAs). 183 lncRNAs were identified with significant dysregulation in glioma and randomly selected differential RNAs were further confirmed by RT-qPCR. Among them, BCYRN1 was the most downregulated lncRNA, and its low expression positively correlated with glioma progression. Functionally, BCYRN1 overexpression inhibited cell proliferation, migration in glioma cell lines, whereas BCYRN1 depletion resulted in the opposite way. MiR-619-5p was further confirmed as the direct target of BCYRN1. Mechanistically, miR-619-5p specifically targeted the CUE domain containing protein 2 (CUEDC2), and BCYRN1/miR-619-5p suppressed glioma tumorigenesis by inactivating PTEN/AKT/p21 pathway in a CUEDC2-dependent manner. Overall, our data presented that the reduced expression of BCYRN1 was associated with poor patient outcome in glioma. BCYRN1 functioned as a ceRNA to inhibit glioma progression by sponging miR-619-5p to regulate CUEDC2 expression and PTEN/AKT/p21 pathway. Our results indicated that BCYRN1 exerted tumor suppressor potential and might be a candidate in the diagnosis and treatment of glioma. |
| PubMedID : | 32978519 |
| Cancer Type(Tumour VS Normal) | BCYRN1 | CUEDC2 | ||||
|---|---|---|---|---|---|---|
| Mean Expression | log2FoldChange | FDR | Mean Expression | log2FoldChange | FDR | |
| BLCA(414 vs 19) | 0.7902592 | 0.019934839 | 0.953975072 | 43.4681236 | -0.084393474 | 0.660433139 |
| BRCA(1142 vs 114) | 1.505897161 | 0.086638012 | 0.614063527 | 47.8317203 | 0.380775169 | 1.15e-08 |
| CESC(306 vs 3) | 0.886197137 | -1.053409306 | 0.31526837 | 46.29323254 | -0.65999935 | 0.166702803 |
| CHOL(36 vs 9) | 0.859306111 | 1.451798744 | 1.9e-07 | 58.68169753 | 0.209344679 | 0.447596321 |
| COAD(505 vs 41) | 0.912686346 | 0.264129043 | 0.202472873 | 37.97269874 | 0.209989211 | 0.035052441 |
| ESCA(185 vs 13) | 9.182498043 | 0.35839034 | 0.534412059 | 28.03885679 | -0.159934501 | 0.518763603 |
| GBM(170 vs 5) | 10.43813015 | -1.485009105 | 0.07891593 | 80.74769119 | -0.326392988 | 0.246844437 |
| HNSC(522 vs 44) | 0.760675192 | 0.457818766 | 0.040358327 | 36.32739427 | -0.192884829 | 0.092458515 |
| KICH(66 vs 25) | 1.914793667 | 1.114640322 | 1.92e-05 | 25.84034055 | -0.632089791 | 2.11e-07 |
| KIRC(546 vs 72) | 1.003428178 | 0.16992605 | 0.26735334 | 49.34358135 | 0.083398863 | 0.230927451 |
| KRIP(291 vs 32) | 0.794299439 | 0.332200397 | 0.12956681 | 65.96364878 | 0.38080996 | 0.000121312 |
| LIHC(374 vs 50) | 0.387677521 | 0.565460715 | 5.76e-05 | 35.09751897 | 0.143897684 | 0.140850941 |
| LUAD(542 vs 59) | 0.988527688 | 0.472477887 | 0.00033533 | 40.23891821 | 0.065660249 | 0.464028095 |
| LUSC(504 vs 51) | 0.929185937 | 0.723006318 | 9.17e-07 | 39.66467847 | -0.021597009 | 0.83154847 |
| PAAD(179 vs 4) | 0.692237905 | -0.373007738 | 0.654000273 | 42.57727202 | -0.072438927 | 0.929038404 |
| PCPG(184 vs 3) | 5.855994679 | 0.693624086 | 0.606763596 | 68.98337353 | -0.115857679 | 0.785354476 |
| PRAD(506 vs 52) | 1.082885895 | 0.747686702 | 3.75e-05 | 63.39546065 | 0.259312204 | 0.005800938 |
| READ(167 vs 10) | 0.825171054 | -0.251083961 | 0.339346161 | 37.52593453 | 0.18782927 | 0.362067999 |
| SARC(263 vs 2) | 1.38650473 | 0.061416664 | 0.985975884 | 68.86794325 | -0.535625148 | 0.568338068 |
| SKCM(472 vs 1) | 0.993533108 | 1.422617385 | 0.999958931 | 53.14279945 | 0.477291315 | 0.999958931 |
| STAD(416 vs 37) | 7.459492656 | -1.245784376 | 7.01e-05 | 25.01456725 | -0.453683933 | 9.44e-06 |
| THCA(513 vs 59) | 0.496555618 | -0.029963343 | 0.878686422 | 57.00014876 | 0.199154322 | 0.000362848 |
| THYM(120 vs 2) | 0.356240475 | -0.10757428 | 0.954904948 | 75.06904467 | 0.880472101 | 0.415106746 |
| UCEC(558 vs 35) | 1.414312228 | 1.003322396 | 6.66e-05 | 62.98694736 | 0.208080417 | 0.113147827 |
Copyright © 2019 College of Bioinformatics Science and Technology, Harbin Medical University All rights reserved.
黑ICP备2022004059号